🏛️ Verified NIH Record • Updated 2026-05-08
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors (NCT05438329)
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects With Advanced/Metastatic Solid Tumors
🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: DualityBio Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1305/BNT325 in subjects with advanced solid tumors.
Who can join: Review the eligibility criteria below.
Location: Site 139 — Bullhead City, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (93 Sites)
Showing the first 25 of 93 sites.
- Site 139 — Bullhead City, Arizona
- Site 103 — Cerritos, California
- Site 136 — La Jolla, California
- Site 127 — Los Angeles, California
- Site 133 — Los Angeles, California
- Site 108 — Los Angeles, California
- Site 131 — Washington D.C., District of Columbia
- Site 122 — Coral Springs, Florida
- Site 142 — Hialeah, Florida
- Site 114 — Margate, Florida
- Site 120 — Miami, Florida
- Site 126 — Ocala, Florida
- Site 140 — Orange City, Florida
- Site 109 — Plantation, Florida
- Site 141 — St. Petersburg, Florida
- Site 117 — Tamarac, Florida
- Site 111 — Honolulu, Hawaii
- Site 134 — Chicago, Illinois
- Site 124 — Dearborn, Michigan
- Site 106 — Detroit, Michigan
- Site 125 — Royal Oak, Michigan
- Site 129 — Las Vegas, Nevada
- Site 160 — Mineola, New York
- Site 116 — New York, New York
- Site 102 — New York, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumor
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
- A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
- QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
- A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
- First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
- A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas
Explore by condition: All Advanced Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.